# Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

> **NCT00086164** · PHASE1,PHASE2 · TERMINATED · sponsor: **Anesiva, Inc.**

## Conditions studied

- Hyperplasia
- Chronic Renal Failure

## Interventions

- **DRUG:** edifoligide (E2F Decoy)

## Key facts

- **NCT ID:** NCT00086164
- **Lead sponsor:** Anesiva, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086164, "Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00086164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*